BCMAxGPRC5D CAR-T therapy (Juno Therapeutics)

N/A

Report date: 2026/02/14 20:00:22

Base Information

Drug NameBCMAxGPRC5D CAR-T therapy (Juno Therapeutics)
Drug Alias NameAnti BCMA and GPRC5D dual targeting CAR T cell therapy (Juno Therapeutics)BCMAxGPRC5D CAR-T therapy (Juno Therapeutics)Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells therapy (Juno Therapeutics)BMS-986453
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-BCMA +[4] 
TargetsB-cell maturation proteinG-protein coupled receptor family C group 5member D
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyFrance +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesJuno Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyJuno Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A